Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5380-5385

  Camacho, Pauline M ^a   Dayal, Amit S ^a   Diaz, Josefina L ^a   Nabhan, Fadi A ^a   Agarwal, Monica ^a   Norton, John G ^a   Robinson, Patricia A ^a   Albain, Kathy S ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HIP; HUMAN; IDIOPATHIC HYPERCALCIURIA; MAJOR CLINICAL STUDY; METABOLIC BONE DISEASE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SPINE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DENSITY; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS;

EID: 56749102955     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7451     Document Type: Article

References (23)

1. France, International Osteoporosis Foundation: Osteoporosis in the European Community: A call to action-audit of policy developments since 1998. Lyon, France, International Osteoporosis Foundation, 2003
2. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767, 2002
3. Camacho P, Miller PD: Osteoporosis: A Guide for Clinicians. Philadelphia, PA, Lippincott Williams & Wilkins, 2007
4. Riggs BL, Khosla S, Melton LJ 3rd: A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773, 1998
5. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302, 2002
6. Painter SE, Kleerekoper M, Camacho PM: Secondary osteoporosis: A review of the recent evidence. Endocr Pract 12:436-445, 2006
7. Tannenbaum C, Clark J, Schwartzman K, et al: Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431-4437, 2002
8. Greep NC, Giuliano AE, Hansen NM, et al: The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114:653-659, 2003
9. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001
10. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
11. Kristensen B, Ejlertsen B, Dalgaard P, et al: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12:992-997, 1994
12. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
13. Geisler J, Lonning PE, Krag LE, et al: Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebocontrolled study. Eur J Cancer 42:2968-2975, 2006
14. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. 17. J Clin Oncol 24:3629-3635, 2006
15. Dowsett M, Jones A, Johnston SR, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995
16. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
17. Eriksen EF, Langdahl B, Vesterby A, et al: Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. J Bone Miner Res 14:1217-1221, 1999
18. Fuller K, Murphy C, Kirstein B, et al: TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143:1108-1118, 2002
19. Hughes DE, Dai A, Tiffee JC, et al: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2:1132-1136, 1996
20. Kousteni S, Bellido T, Plotkin LI, et al: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730, 2001
21. Weitzmann MN, Pacifici R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 116:1186-1194, 2006
22. Hershman DL, Irani D, Cucchiara K, et al: High prevalence of vitamin D deficiency in premenopausal women with early-stage breast cancer. J Clin Oncol 24:485s, 2006 (suppl; abstr 8568)
23. Palmieri C, MacGregor T, Girgis S, et al: Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 59:1334-1336, 2006